How to appeal a Highmark sickle cell & thalassemia denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Highmark-specific note: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.

What Highmark's policy requires for sickle cell & thalassemia

Cited policy: BCBS plan-specific (Empire/Highmark/Florida Blue) gene therapy policies

FDA-approved + ATC + severe disease genotype + transfusion-dependent for TDT.

How Highmark denies sickle cell & thalassemia — and how to counter it

Where Highmark pushes back: 1) State plan more restrictive than FDA label; 2) ATC not in network; 3) Outcomes-based contract not finalized.

Counter-arguments that hold up: Pull plan-specific bulletin. Cite state insurance commissioner external review. NMDP donor search documentation if HSCT discussed. CMS CGT Access Model participation if Medicaid.

What Highmark typically denies for sickle cell & thalassemia

Across Highmark's commercial and Medicare books, denials cluster around a small number of patterns. For sickle cell & thalassemia, expect:

• Prior auth on biologics
• PA on advanced imaging
• OON balance bills

Treatments most often denied in this category

These are the sickle cell & thalassemia treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Casgevy
• Lyfgenia
• Zynteglo
• Allogeneic HSCT
• Hydroxyurea
• Adakveo

How to submit the appeal to Highmark

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Highmark cited in the denial.
3. File the appeal through Highmark's portal (members: https://www.highmark.com ; providers: https://www.highmark.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Highmark's prior-authorization criteria by drug: Highmark PA criteria on ApprovalHelp.